Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Cyclerion Therapeutics (CYCN) Accumulated Depreciation & Amortization (2018 - 2022)

Cyclerion Therapeutics has reported Accumulated Depreciation & Amortization over the past 5 years, most recently at $2.2 million for Q4 2022.

  • For Q4 2022, Accumulated Depreciation & Amortization fell 0.86% year-over-year to $2.2 million; the TTM value through Dec 2022 reached $2.2 million, down 0.86%, while the annual FY2022 figure was $2.2 million, 0.86% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2022 was $2.2 million at Cyclerion Therapeutics, down from $2.3 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $31.0 million in Q3 2019 and troughed at $2.1 million in Q2 2021.
  • A 5-year average of $12.1 million and a median of $10.3 million in 2020 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 39.45% in 2019 and later tumbled 90.02% in 2021.
  • Year by year, Accumulated Depreciation & Amortization stood at $15.5 million in 2018, then soared by 39.45% to $21.6 million in 2019, then plummeted by 52.38% to $10.3 million in 2020, then tumbled by 78.61% to $2.2 million in 2021, then decreased by 0.86% to $2.2 million in 2022.
  • Business Quant data shows Accumulated Depreciation & Amortization for CYCN at $2.2 million in Q4 2022, $2.3 million in Q3 2022, and $2.3 million in Q2 2022.